David Fairen-Jimenez on Reducing Toxicity With Highly Targeted Polymeric Nanoparticles

News
Video

Vector Bioscience Cambridge is developing highly porous nanomaterials that can help reduce toxicities due to the small amount of vehicle material.

With a focus on improving drug delivery, David Fairen-Jimenez, PhD, and his company, Vector Bioscience Cambridge, have carved out their corner of precision medicine with their platform that utilizes high-porosity nanomaterials to deliver targeted treatments with less toxicity.

Fairen-Jimenez, professor of mechanical engineering at the University of Cambridge in the UK, and CEO and co-founder of Vector Bioscience Cambridge, spoke to Biopharm International during the Precision Medicine World Congress to provide an overview of the company's technology and platform.

"We have a family of materials...essentially some polymeric nanoparticles that are called porous coordination polymers, which are extremely porous materials. In a single gram of material—we're talking about several 1000s of square meters—these materials can encapsulate different drug molecules inside the porosity, while we have a very, very tiny amount of vehicle, and this means the toxic effects of these vehicles are really, really low," Fairen-Jimenez said.

The company's pipeline is focused on oncology, where they are currently exploring at least seven molecules, two of which have advanced to in vivo studies in pancreatic and breast cancer.

"We have a huge amount of flexibility that is very difficult to reproduce with other types of nanoparticles," he said. "On the one hand, we have been able to... encapsulate molecules so we have a slow release for one month, for example, inside the body. We have other examples where we have been able to put RNA molecules to knock down the expression of proteins, and that's a great advantage against any other technology. The bottleneck for RNA therapies, many times, is the transport of these RNAs inside the cells, outside of the lysosomes. So being able to really unlock the potential of these RNAs has been great."

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.